checkAd
    Startseite > Aktien > Replimune Group > Nachrichten
    Replimune Group Aktie
    4,7600
     
    EUR
    +2,59 %
    +0,1200 EUR
    Letzter Kurs 17:55:06 Tradegate
    4,6200
     
    EUR
    900 STK
    Geldkurs 20:46:56
    4,7000
     
    EUR
    900 STK
    Briefkurs 20:46:56
    ISIN: US76029N1063 · WKN: A2JQN1 · SYM: 7R8 · USA

    Neueste Nachrichten

    Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    23.05.24 · globenewswire · Replimune Group
    Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update
    16.05.24 · globenewswire · Replimune Group
    Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
    07.04.24 · globenewswire · Replimune Group
    Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    04.04.24 · globenewswire · Replimune Group
    Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions
    26.03.24 · globenewswire · Replimune Group
    Replimune to Present at the American Association for Cancer Research Annual Meeting 2024
    06.03.24 · globenewswire · Replimune Group
    Replimune to Present at Three Upcoming Investor Conferences
    05.03.24 · globenewswire · Replimune Group
    Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
    08.02.24 · globenewswire · Replimune Group
    Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    28.12.23 · globenewswire · Replimune Group
    Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research
    08.11.23 · globenewswire · Replimune Group
    Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update
    07.11.23 · globenewswire · Replimune Group
    Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherap
    04.11.23 · globenewswire · Replimune Group